Search
  • Griffin O'Driscoll

Who we are and what we do

Organicin is a drug discovery company capitalizing on the shifting market forces of agriculture

Agriculture is undergoing rapid change in response to: (i) antimicrobial resistance (AMR); (ii) climate change (decreased arable land, increased pathogen virulence); (iii) consumer and regulator calls for sustainability; (iv) a growing population.


We believe these factors converge into a massive (VC-sized) opportunity to create and capture value in the global Ag/Aquaculture “crop” protection markets alone.


How? Traditional agricultural practices prioritized output over sustainability and resilience. Organicin Scientific is differentiated by the fact that our drug discovery platform does not make this tradeoff. The problem is bacterial diseases are destroying our crops and current treatments are unremarkable or worse, ineffective. Our solution is a bacteriocin-based therapeutic that designs out the destruction of biodiversity & the need for harmful antibiotics.


We are building a bacteriocin-based discovery platform to identify & optimize novel drug candidates

Bacteriocins are naturally occurring antimicrobial proteins elicited from bacteria. They have numerous characteristics that underscore their potential in agriculture: (i) display selective antibiosis - sparing the microbiome from collateral damage and preserving beneficial bacteria (supporting plant growth and nutrient uptake); (ii) their mechanism of action significantly reduces rates of resistance emergence; (iii) remarkably potent, often killing instantly as well as displaying stability under a wide range of environmental conditions including the soil microrhizome and plant tissue; (iv) biodegradable via proteolytic enzymes (no accumulation in soil or water column); (v) industrial production methods (i.e. fermentation) exist which result in high levels of protein expression and cost-effective production, while meeting the requirements of EPA regulatory approval as a biopesticide (accelerated time frame).


Our company is leveraging these characteristics to develop a first-of-its-kind bacteriocin-based biopesticide, providing an alternative solution to the “last-resort” antibiotic (e.g. streptomycin and oxytetracycline) spraying on our crops. We are currently developing a product for fire blight disease, an economically-devasting apple disease. The success of this project will serve as a prototype for our platform tech, which will be used to expand bacteriocin-based biopesticides beyond a singular disease.


We are raising funds to progress past in vitro studies and provide proof-of-concept via plant models and larger greenhouse studies. In essence, we have proved it works in the lab and now we need to prove it works in the plant to attract funding for scale up and regulatory studies.


Preliminary in-vitro data supports bacteriocins as a superior biopesticide active-ingredient

Our platform produced 53 leads on first run (8 weeks). We have successfully identified drug candidates that inhibit Erwinia Amylovora, the causative agent of fire blight. Platform has shown that bacteria strains (isolates) are 4x more likely to inhibit phytopathogens than plant growth-promoting rhizobacteria (PGPR). We find a lead against a phytopathogen every 20 isolates tested. Essentially, we are able to design a biopesticide that kills the pathogen and increases yield by leaving growth-promoting bacteria alone.

56 views0 comments